Respironics ( RESP - NASDAQ ) has just reported the last Q results . Part of RESPIRONICS biz is actually the second leg in the DUOPOLY of RMD/RESP in the APNEA sleep disorder market . Key drivers for the Company's domestic revenue performance include a year-over-year increase of 15 percent in domestic sleep therapy products. Let's hope RMD did the same . First call consensus expected increase for RMD is 12% in EPS growth .It is expected to report EPS USc 28 for the Q and USD 1.06 for the FY , Duff
RMD - A possible profit clue
Add RMD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.94 |
Change
-0.130(0.62%) |
Mkt cap ! $30.20B | |||
| Open | High | Low | Value | Volume |
| $21.04 | $21.06 | $20.91 | $2.727M | 129.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 794 | $20.93 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.94 | 6 | 1 |
View Market Depth
| Last trade - 11.04am 12/11/2019 (20 minute delay) ? |
 (live)
|
|||||
|
Last
$21.00 |
Change
-0.130 ( 0.14 %) |
||||
| Open | High | Low | Volume | ||
| $21.03 | $21.05 | $20.92 | 21036 | ||
| Last updated 11.24am 12/11/2019 (live) ? | |||||
| RMD (ASX) Chart |